Kwality Pharma Q4 Revenue Up 35.8% to ₹157.1 Crore

Kwality Pharmaceuticals reported Q4FY26 revenue growth of 35.8% to ₹157.1 crore and full-year revenue of ₹503 crore, up 36% YoY.
PAT grew 69% to ₹67 crore for FY26 with EBITDA margins expanding from 22% to 24% due to operational efficiencies.
Management provided FY27 guidance of ₹650 crore revenue and ₹100 crore PAT, targeting ₹1,000 crore revenue by FY29.
Company discussed expansion in oncology, hormones, and biosimilars with planned capex of ₹260-270 crore over FY27-28.